What is Zacks Research’s Forecast for TSE:BHC Q2 Earnings?

Bausch Health Companies Inc. (TSE:BHC) – Equities research analysts at Zacks Research raised their Q2 2026 EPS estimates for Bausch Health Companies in a report issued on Wednesday, March 11th. Zacks Research analyst Team now expects that the company will earn $1.28 per share for the quarter, up from their prior forecast of $1.27. The consensus estimate for Bausch Health Companies’ current full-year earnings is $5.55 per share. Zacks Research also issued estimates for Bausch Health Companies’ Q3 2027 earnings at $1.52 EPS and FY2028 earnings at $4.56 EPS.

Bausch Health Companies (TSE:BHC) last released its quarterly earnings results on Wednesday, February 18th. The company reported C($0.41) earnings per share (EPS) for the quarter. The firm had revenue of C$6.62 billion during the quarter. Bausch Health Companies had a negative return on equity of 20.27% and a net margin of 1.82%.

A number of other research analysts have also recently commented on the company. Raymond James Financial upgraded Bausch Health Companies to a “hold” rating in a report on Monday, December 15th. Barclays raised Bausch Health Companies to a “hold” rating in a research report on Monday, December 8th. Two analysts have rated the stock with a Hold rating, According to data from MarketBeat, the company currently has an average rating of “Hold”.

Bausch Health Companies Stock Down 1.0%

Shares of BHC stock opened at C$6.82 on Friday. The company has a debt-to-equity ratio of -3,835.02, a current ratio of 1.47 and a quick ratio of 0.58. The company has a market cap of C$2.53 billion, a price-to-earnings ratio of 16.24, a price-to-earnings-growth ratio of 0.21 and a beta of 0.60. The stock’s fifty day moving average price is C$8.50 and its 200 day moving average price is C$9.04. Bausch Health Companies has a 1-year low of C$5.91 and a 1-year high of C$11.97.

More Bausch Health Companies News

Here are the key news stories impacting Bausch Health Companies this week:

• Positive Sentiment: Zacks raised near-term quarterly EPS forecasts: Q3 2027 to $1.52 (from $1.42) and Q2 2026 to $1.28 (from $1.27), signalling some upside in cadence of upcoming quarters that could support short‑term earnings beats. Read More.
• Positive Sentiment: Zacks also lifted Q4 2026 to $1.49 (from $1.46) and Q1 2027 to $1.11 (from $1.09), indicating modestly stronger expected results in several sequential quarters. Read More.
• Neutral Sentiment: Zacks published a FY2028 EPS outlook of $4.56 — useful for long‑term modeling but two years out and unlikely to drive immediate price action. Read More.
• Negative Sentiment: Offsetting the raises, Zacks cut several near‑term and full‑year estimates: Q1 2026 to $1.10 (from $1.13), Q3 2026 to $1.44 (from $1.50) and Q2 2027 to $1.20 (from $1.32), reflecting weaker expected performance in key quarters. Read More.
• Negative Sentiment: Zacks trimmed FY2026 to $5.32 (from $5.37) and cut FY2027 to $5.15 (from $5.30); it also lowered Q4 2027 to $1.32 (from $1.47). Those downward revisions weigh on medium‑term earnings visibility and likely contributed to selling pressure. Read More.

Bausch Health Companies Company Profile

Bausch Health Companies Inc is a global company that develops manufactures and markets a range of pharmaceutical medical device and over-the-counter products primarily in the therapeutic areas of eye health gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health. Our approximately 22000 employees are united around our mission of improving peoples lives with our health care products and we manufacture and market health care products directly or indirectly in approximately 100 countries.